A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Na√Øve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3